Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D.
Turn Therapeutics (Nasdaq: TTRX) announced that CEO Bradley Burnam spoke with Dr. Robert Redfield, former CDC director, on Nov 11, 2025 about healthcare communications and restoring public trust in science.
The interview, titled "Redfield’s Warning: Former CDC Director on COVID’s Biggest Casualty-Trust in Science", is available on major podcast platforms, YouTube, and the Turn Therapeutics investor relations website. The conversation emphasizes fact-based science, data-driven public health messaging, and continued dialogue between biotech leaders and public officials.
Dr. Redfield is described as a virologist who led CDC from 2018–2021 and contributed to early HIV research including the Walter Reed staging system and evidence of active HIV replication across disease stages.
Turn Therapeutics (Nasdaq: TTRX) ha annunciato che il CEO Bradley Burnam ha parlato con il dottor Robert Redfield, ex direttore del CDC, l'11 novembre 2025 riguardo alle comunicazioni sanitarie e al ripristino della fiducia pubblica nella scienza.
L'intervista, intitolata "Redfield’s Warning: Former CDC Director on COVID’s Biggest Casualty-Trust in Science", è disponibile sulle principali piattaforme di podcast, YouTube e sul sito di relazioni con gli investitori di Turn Therapeutics. La conversazione enfatizza la scienza basata sui fatti, la comunicazione di sanità pubblica guidata dai dati e il continuo dialogo tra leader biotecnologici e funzionari pubblici.
Il dottor Redfield è descritto come virologo che ha guidato il CDC dal 2018 al 2021 e ha contribuito a ricerche HIV iniziali tra cui il sistema di staging di Walter Reed e prove di replicazione attiva dell'HIV attraverso le fasi della malattia.
Turn Therapeutics (Nasdaq: TTRX) anunció que el CEO Bradley Burnam habló con el Dr. Robert Redfield, ex director de los CDC, el 11 de noviembre de 2025 sobre comunicaciones de salud y restablecer la confianza del público en la ciencia.
La entrevista, titulada "Redfield’s Warning: Former CDC Director on COVID’s Biggest Casualty-Trust in Science", está disponible en las principales plataformas de podcasts, YouTube y en el sitio de relaciones con inversionistas de Turn Therapeutics. La conversación enfatiza la ciencia basada en hechos, mensajes de salud pública impulsados por datos y el continuo diálogo entre líderes de biotecnología y funcionarios públicos.
El Dr. Redfield se describe como virólogo que dirigió los CDC de 2018 a 2021 y que contribuyó a la investigación temprana del VIH, incluyendo el sistema de staging de Walter Reed y evidencias de replicación activa del VIH a través de las etapas de la enfermedad.
Turn Therapeutics (Nasdaq: TTRX)는 CEO 브래들리 번엄이 2025년 11월 11일 Dr. Robert Redfield(전 CDC 국장)와 건강 관리 커뮤니케이션 및 과학에 대한 대중의 신뢰 회복에 대해 대화했다고 발표했습니다.
인터뷰 제목은 "Redfield’s Warning: Former CDC Director on COVID’s Biggest Casualty-Trust in Science"이며 주요 팟캐스트 플랫폼, 유튜브 및 Turn Therapeutics 투자자 관계 웹사이트에서 이용 가능합니다. 대화는 사실 기반의 과학, 데이터에 기반한 공중 보건 메시지, 그리고 바이오테크 리더와 공공 당국 간의 지속적인 대화를 강조합니다.
Redfield 박사는 2018년부터 2021년까지 CDC를 이끌었고 Walter Reed의 스테이지 시스템과 질병 단계 전반에 걸친 활동적 HIV 복제 증거를 포함한 초기 HIV 연구에 기여한 바이로로지스트로 소개됩니다.
Turn Therapeutics (Nasdaq: TTRX) a annoncé que le PDG Bradley Burnam s’est entretenu avec le Dr Robert Redfield, ancien directeur du CDC, le 11 novembre 2025, sur les communications en santé et la restauration de la confiance du public dans la science.
L’interview, intitulée "Redfield’s Warning: Former CDC Director on COVID’s Biggest Casualty-Trust in Science", est disponible sur les principales plateformes de podcasts, YouTube et le site des relations investisseurs de Turn Therapeutics. La conversation met l’accent sur une science fondée sur les faits, des messages de santé publique basés sur les données et un dialogue continu entre les dirigeants de biotechnologie et les responsables publics.
Le Dr Redfield est décrit comme virologue ayant dirigé le CDC de 2018 à 2021 et ayant contribué à des recherches initiales sur le VIH, notamment le système de staging de Walter Reed et des preuves de réplication active du VIH à travers les stades de la maladie.
Turn Therapeutics (Nasdaq: TTRX) gab bekannt, dass CEO Bradley Burnam am 11. November 2025 mit Dr. Robert Redfield, dem ehemaligen CDC-Direktor, über Gesundheitskommunikation und den Aufbau des öffentlichen Vertrauens in die Wissenschaft sprach.
Das Interview mit dem Titel "Redfield’s Warning: Former CDC Director on COVID’s Biggest Casualty-Trust in Science" ist auf großen Podcast-Plattformen, YouTube und der Investor Relations-Website von Turn Therapeutics verfügbar. Das Gespräch betont faktenbasierte Wissenschaft, datengestützte öffentliche Gesundheitskommunikation und den fortgesetzten Dialog zwischen Biotech-Führungskräften und öffentlichen Beamten.
Dr. Redfield wird als Virologe beschrieben, der das CDC von 2018 bis 2021 leitete und zu frühen HIV-Forschungen beitrug, darunter das Walter Reed-Staging-System und Nachweise aktiver HIV-Replikation über die Krankheitsstadien hinweg.
Turn Therapeutics (Nasdaq: TTRX) أعلنت أن المدير التنفيذي Bradley Burnam تحدث مع الدكتور روبرت ريدفيلد، المدير السابق لـ CDC، في 11 نوفمبر 2025 حول اتصالات الرعاية الصحية واستعادة الثقة العامة في العلم.
المقابلة بعنوان "تحذير Redfield: المدير السابق لـ CDC عن أكبر ضحايا COVID - الثقة في العلم" متاحة على منصات البودكاست الرئيسية، YouTube، وموقع علاقات المستثمرين لـ Turn Therapeutics. تؤكد المحادثة على العلم المستند إلى الحقائق، والرسائل الصحية العامة القائمة على البيانات، واستمرار الحوار بين قادة التكنولوجيا الحيوية والمسؤولين الحكوميين.
يوصف الدكتور Redfield بأنه عالم فيروسات قاد CDC من 2018 إلى 2021 وساهم في أبحاث مبكرة عن فيروس HIV بما في ذلك نظام التصنيف في Walter Reed وأدلة على تكرار فيروسات HIV النشط عبر مراحل المرض.
- None.
- None.
Conversation Centered Around Healthcare Communications and Pandemic Preparedness
LOS ANGELES, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today announced that Chief Executive Officer, Brad Burnam, spoke with Dr. Robert Redfield, M.D., former Director of the Centers for Disease Control and Prevention (CDC) about healthcare communication and ways to restore public trust in science. The interview, titled “Redfield’s Warning: Former CDC Director on COVID’s Biggest Casualty-Trust in Science,” can be accessed on all major podcast platforms, via YouTube here, or on the Turn Therapeutics IR Website here.
“It was a pleasure speaking with Dr. Redfield about re-improving public trust in health authorities,” said Bradley Burnam, Founder and Chief Executive Officer of Turn Therapeutics. “There is an obligation that companies and public health authorities have to report fact-based science to the American people. Dr. Redfield is a champion of that sentiment. I look forward to continuing the conversation not only with Dr. Redfield but with other, similar, government officials so that both biotech executives and other public facing health figures can further restore public trust in science.”
Dr. Robert Redfield, M.D., is a virologist who served as the director for the CDC from 2018 to 2021. During his tenure, Dr. Redfield was a strong advocate for science-based and data-driven decision-making. Earlier in his career, Dr. Redfield made several important early contributions to the scientific understanding of HIV including the development of the Walter Reed staging system for HIV infection and the demonstration of active HIV replication in all stages of HIV infection.
About Turn Therapeutics
Turn Therapeutics is a biotechnology company developing and commercializing products for dermatology, wound care, and infectious disease. The Company has received three FDA clearances for its proprietary wound and dermatology formulations and is advancing late-stage clinical programs in eczema and onychomycosis. In addition, Turn is pursuing global health initiatives in thermostable vaccine delivery designed to serve underserved areas worldwide, reflecting its commitment to public health innovation.
Forward-Looking Statement
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Turn’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict, including risks related to the timing and effectiveness of the Company’s registration statement, the success of development programs, and the Company’s ability to execute its strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Turn Therapeutics in general, see the risk disclosures in the Company’s filings with the SEC. All such forward-looking statements speak only as of the date they are made, and Turn undertakes no obligation to update or revise these statements, whether as a result of new information, future events, or otherwise.
Investor Relations:
Monique Kosse, Managing Director
Gilmartin Group
Investors@TurnTherapeutics.com
Media Contact:
media@TurnTherapeutics.com
FAQ
What did Turn Therapeutics (TTRX) announce on November 11, 2025?
Where can investors listen to the Turn Therapeutics and Dr. Robert Redfield interview?
What is the title of the Turn Therapeutics podcast featuring Dr. Robert Redfield?
Why did Turn Therapeutics (TTRX) host a conversation with Dr. Robert Redfield?
What are Dr. Robert Redfield’s relevant credentials mentioned in the TTRX announcement?
Does the Turn Therapeutics announcement include new clinical or financial data for TTRX?
